Lexicon Resubmits Sotagliflozin NDA for Type 1 Diabetes
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease
Company Anticipates Six Month Review and Potential Launch in Early 2025
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.